vs

Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

CB Financial Services, Inc. is the larger business by last-quarter revenue ($13.8M vs $11.6M, roughly 1.2× SUTRO BIOPHARMA, INC.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -21.4%). Over the past eight quarters, CB Financial Services, Inc.'s revenue compounded faster (1.2% CAGR vs -5.4%).

CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

CBFV vs STRO — Head-to-Head

Bigger by revenue
CBFV
CBFV
1.2× larger
CBFV
$13.8M
$11.6M
STRO
Growing faster (revenue YoY)
CBFV
CBFV
+41.2% gap
CBFV
19.9%
-21.4%
STRO
Faster 2-yr revenue CAGR
CBFV
CBFV
Annualised
CBFV
1.2%
-5.4%
STRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBFV
CBFV
STRO
STRO
Revenue
$13.8M
$11.6M
Net Profit
Gross Margin
Operating Margin
38.1%
Net Margin
Revenue YoY
19.9%
-21.4%
Net Profit YoY
35.4%
EPS (diluted)
$0.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBFV
CBFV
STRO
STRO
Q4 25
$13.8M
$11.6M
Q3 25
$2.4M
$9.7M
Q2 25
$13.5M
$63.7M
Q1 25
$12.1M
$17.4M
Q4 24
$13.2M
$14.8M
Q3 24
$12.7M
$8.5M
Q2 24
$12.2M
$25.7M
Q1 24
$13.5M
$13.0M
Net Profit
CBFV
CBFV
STRO
STRO
Q4 25
Q3 25
$-5.7M
$-56.9M
Q2 25
$3.9M
$-11.5M
Q1 25
$1.9M
$-76.0M
Q4 24
$-72.4M
Q3 24
$3.2M
$-48.8M
Q2 24
$2.6M
$-48.0M
Q1 24
$4.2M
$-58.2M
Operating Margin
CBFV
CBFV
STRO
STRO
Q4 25
38.1%
Q3 25
-289.8%
-499.9%
Q2 25
35.0%
-5.2%
Q1 25
19.3%
-393.8%
Q4 24
23.1%
-440.7%
Q3 24
31.2%
-797.2%
Q2 24
26.4%
-189.4%
Q1 24
37.9%
-435.0%
Net Margin
CBFV
CBFV
STRO
STRO
Q4 25
Q3 25
-235.2%
-586.6%
Q2 25
29.3%
-18.0%
Q1 25
15.8%
-436.6%
Q4 24
-489.2%
Q3 24
25.3%
-572.6%
Q2 24
21.8%
-186.8%
Q1 24
31.1%
-447.5%
EPS (diluted)
CBFV
CBFV
STRO
STRO
Q4 25
$0.90
Q3 25
$-1.07
$-0.67
Q2 25
$0.74
$-0.14
Q1 25
$0.35
$-0.91
Q4 24
$0.45
$-27.63
Q3 24
$0.60
$-0.59
Q2 24
$0.51
$-0.59
Q1 24
$0.82
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBFV
CBFV
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$31.7M
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$157.5M
$-132.5M
Total Assets
$1.5B
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBFV
CBFV
STRO
STRO
Q4 25
$31.7M
$141.4M
Q3 25
$55.9M
$167.6M
Q2 25
$64.5M
$205.1M
Q1 25
$61.3M
$249.0M
Q4 24
$49.6M
$316.9M
Q3 24
$147.3M
$388.3M
Q2 24
$142.6M
$375.6M
Q1 24
$73.7M
$267.6M
Stockholders' Equity
CBFV
CBFV
STRO
STRO
Q4 25
$157.5M
$-132.5M
Q3 25
$152.5M
$-87.3M
Q2 25
$148.4M
$-32.1M
Q1 25
$148.3M
$-25.8M
Q4 24
$147.4M
$44.6M
Q3 24
$149.1M
$111.2M
Q2 24
$142.9M
$152.2M
Q1 24
$141.6M
$98.0M
Total Assets
CBFV
CBFV
STRO
STRO
Q4 25
$1.5B
$173.8M
Q3 25
$1.5B
$209.7M
Q2 25
$1.5B
$262.4M
Q1 25
$1.5B
$321.4M
Q4 24
$1.5B
$387.2M
Q3 24
$1.6B
$451.8M
Q2 24
$1.6B
$489.0M
Q1 24
$1.5B
$403.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBFV
CBFV
STRO
STRO
Operating Cash FlowLast quarter
$17.8M
$-177.2M
Free Cash FlowOCF − Capex
$17.2M
FCF MarginFCF / Revenue
124.1%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBFV
CBFV
STRO
STRO
Q4 25
$17.8M
$-177.2M
Q3 25
$4.6M
$-38.2M
Q2 25
$4.1M
$-44.7M
Q1 25
$4.0M
$-67.9M
Q4 24
$6.8M
$-71.7M
Q3 24
$3.1M
$-64.5M
Q2 24
$-1.2M
$9.5M
Q1 24
$3.3M
$-64.7M
Free Cash Flow
CBFV
CBFV
STRO
STRO
Q4 25
$17.2M
Q3 25
$4.5M
Q2 25
$3.9M
Q1 25
$3.9M
Q4 24
$3.4M
Q3 24
$2.2M
Q2 24
$-2.4M
Q1 24
$2.3M
FCF Margin
CBFV
CBFV
STRO
STRO
Q4 25
124.1%
Q3 25
186.5%
Q2 25
28.8%
Q1 25
32.5%
Q4 24
26.0%
Q3 24
17.4%
Q2 24
-19.6%
Q1 24
17.0%
Capex Intensity
CBFV
CBFV
STRO
STRO
Q4 25
4.7%
Q3 25
4.3%
Q2 25
1.9%
Q1 25
0.8%
Q4 24
25.1%
Q3 24
6.7%
Q2 24
10.0%
Q1 24
7.2%
Cash Conversion
CBFV
CBFV
STRO
STRO
Q4 25
Q3 25
Q2 25
1.05×
Q1 25
2.11×
Q4 24
Q3 24
0.95×
Q2 24
-0.44×
Q1 24
0.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons